SG11201802470SA - Egfr kinase inhibitor and preparation method and use thereof - Google Patents

Egfr kinase inhibitor and preparation method and use thereof

Info

Publication number
SG11201802470SA
SG11201802470SA SG11201802470SA SG11201802470SA SG11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA SG 11201802470S A SG11201802470S A SG 11201802470SA
Authority
SG
Singapore
Prior art keywords
preparation
kinase inhibitor
egfr kinase
egfr
inhibitor
Prior art date
Application number
SG11201802470SA
Inventor
Dawei Ma
Qiang Yu
Junying Yuan
Hongguang Xia
Dongpo Cai
Kailiang Wang
Chen Zhang
Shanghua Xia
Original Assignee
Zhejiang Bossan Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhejiang Bossan Pharmaceutical Co Ltd filed Critical Zhejiang Bossan Pharmaceutical Co Ltd
Publication of SG11201802470SA publication Critical patent/SG11201802470SA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
SG11201802470SA 2015-09-25 2016-07-11 Egfr kinase inhibitor and preparation method and use thereof SG11201802470SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510622837.4A CN106554347B (en) 2015-09-25 2015-09-25 EGFR kinase inhibitor and preparation method and application thereof
PCT/CN2016/089679 WO2017049992A1 (en) 2015-09-25 2016-07-11 Egfr kinase inhibitor and preparation method and use thereof

Publications (1)

Publication Number Publication Date
SG11201802470SA true SG11201802470SA (en) 2018-04-27

Family

ID=58385839

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201802470SA SG11201802470SA (en) 2015-09-25 2016-07-11 Egfr kinase inhibitor and preparation method and use thereof

Country Status (12)

Country Link
US (1) US10710979B2 (en)
EP (1) EP3354647B1 (en)
JP (1) JP6752283B2 (en)
KR (1) KR20180096575A (en)
CN (1) CN106554347B (en)
AU (1) AU2016327857B2 (en)
BR (1) BR112018005795A2 (en)
CA (1) CA2999785C (en)
RU (1) RU2018115278A (en)
SG (1) SG11201802470SA (en)
WO (1) WO2017049992A1 (en)
ZA (1) ZA201802141B (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI778943B (en) 2015-10-01 2022-10-01 美商潛能醫療有限公司 Anti-tigit antigen-binding proteins and methods of use thereof
JOP20190203A1 (en) 2017-03-30 2019-09-03 Potenza Therapeutics Inc Anti-tigit antigen-binding proteins and methods of use thereof
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020245208A1 (en) 2019-06-04 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of cd9 as a biomarker and as a biotarget in glomerulonephritis or glomerulosclerosis
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20110025224A (en) * 2008-06-27 2011-03-09 아빌라 테라퓨틱스, 인크. Heteroaryl compounds and uses thereof
US8338439B2 (en) * 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI545115B (en) 2010-11-01 2016-08-11 阿維拉製藥公司 Heterocyclic compounds and uses thereof
JP5957003B2 (en) * 2010-11-10 2016-07-27 セルジーン アヴィロミクス リサーチ, インコーポレイテッド Mutant selective EGFR inhibitor and use thereof
CN104583195B (en) * 2012-09-12 2018-08-17 山东亨利医药科技有限责任公司 Nitrogenous heteroaromatic ring derivative as tyrosine kinase inhibitor
NO2718543T3 (en) * 2014-02-04 2018-01-06
CN104860890B (en) * 2015-04-29 2018-03-13 上海泓博智源医药股份有限公司 T790M mutant egfs R inhibitor and its application in antineoplastic is prepared
CN105461640B (en) 2015-12-02 2017-11-21 芷威(上海)化学科技有限公司 A kind of preparation method of tyrosine kinase inhibitor

Also Published As

Publication number Publication date
CN106554347A (en) 2017-04-05
CA2999785A1 (en) 2017-03-30
EP3354647B1 (en) 2022-08-24
JP6752283B2 (en) 2020-09-09
WO2017049992A1 (en) 2017-03-30
JP2018536698A (en) 2018-12-13
AU2016327857B2 (en) 2019-10-03
US20180346444A1 (en) 2018-12-06
CA2999785C (en) 2020-10-27
RU2018115278A3 (en) 2019-10-28
US10710979B2 (en) 2020-07-14
RU2018115278A (en) 2019-10-28
BR112018005795A2 (en) 2019-01-15
EP3354647A4 (en) 2019-04-03
KR20180096575A (en) 2018-08-29
CN106554347B (en) 2020-10-30
AU2016327857A1 (en) 2018-04-26
ZA201802141B (en) 2019-01-30
EP3354647A1 (en) 2018-08-01

Similar Documents

Publication Publication Date Title
IL279258B (en) Tyrosine kinase inhibitors
HK1252693A1 (en) Inhibitors of egfr and methods of use thereof
HK1248231A1 (en) Substituted quinazoline compounds and methods of use thereof
ZA201701465B (en) Egfr inhibitor, and preparation and application thereof
HK1246286A1 (en) Lrrk2 inhibitors and methods of making and using the same
IL259711A (en) Protein kinase inhibitor, preparation method and medical use thereof
PL3277681T3 (en) Imidazolonylquinolines and their use as atm kinase inhibitors
HK1249497A1 (en) Ebna1 inhibitors and methods using same
ZA201700021B (en) Alk kinase inhibitor, and preparation method and use thereof
GB201514760D0 (en) Compounds and method of use
ZA201802141B (en) Egfr kinase inhibitor and preparation method and use thereof
HK1250028A1 (en) 2-phenyl-6-imidazolyl-pyridine-4-carboxamide derivatives and their use as eaat3 inhibitors
HK1250926A1 (en) Inhibitors and their uses
ZA201903845B (en) Fgfr4 inhibitor and preparation method and use thereof
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201505975D0 (en) Inhibitors and their uses
GB201505971D0 (en) Inhibitors and their uses
GB201502247D0 (en) Formulation and method